News | Sirnaomics

Press Release

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

2023.06.01

Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

2023.05.17

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase I Trial of RV-1730 COVID-19 Booster Vaccine

2023.04.27

Sirnaomics in the News

MoCo biopharma Sirnaomics more than triples footprint with new HQ

2022-12

Exclusive: Sirnaomics hopes to develop non-melanoma skin cancer therapy with its siRNA

2022-09

Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year

2022-08

Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases

2022-08

After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology

2022-02

Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public

2021-07

RNA Silencing Finds Its Therapeutic Voice

2020-03

Hunt for New Coronavirus Treatments Includes Gene-Silencing And Monoclonal Antibodies

2020-02

Media Outreach

Sirnaomics Ltd.

401 Professional Dr, STE 280，Gaithersburg, MD 20879, USA

Alexis Feinberg

Tel: +1 203 939 2225